IP Library › Granted Patent US 11,402,372
Granted Patent B2
US 11,402,372 · App. 16/244,667 · Granted Aug 2, 2022

Methods for screening cereblon modifying compounds

Inventors: Mary Matyskiela (San Diego, CA); Philip Chamberlain (San Diego, CA); Suzana Sturlini Couto (La Jolla, CA); Katherine Stamp (Montclair, NJ); Philip J. Sherratt (Scotch Plains, NJ); Gang Lu (San Diego, CA); Julia Hui (Basking Ridge, NJ)
Assignee: CELGENE CORPORATION
G01N33/502G01N33/5014G01N33/5017G01N33/6872G01N2333/46G01N2800/385
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,402,372
App. No.
16/244,667
Granted
Aug 2, 2022
Kind
B2
Abstract

A method of screening a cereblon modifying compound for treating a disease or disorder, comprising: obtaining a sample; determining a first protein level of SALL 4 ; administering the cereblon modifying compound to the sample; determining a second protein level of SALL 4 ; comparing the first level and the second protein level of SALL 4 to determine if the cereblon modifying compound induces degradation of SALL 4 ; and selecting the cereblon modifying compound that does not induce degradation of SALL 4.

Claims (10)

1. A method of screening a cereblon modifying compound, comprising:

(a) obtaining a sample containing Sal-like protein 4 (SALL 4 ) and cereblon;

(b) administering the cereblon modifying compound to the sample;

(c) determining an interaction between the SALL 4 and the cerebion after step (b), wherein the interaction between the SALL 4 and the cereblon is determined by determining the interaction between amino acid residues 405 - 432 of the SALL 4 protein (SEQ ID NO: 3) and the cereblon or by determining the interaction between amino acid residues 410 - 432 of the SALL 4 protein (SEQ ID NO: 11 ) and the cereblon; and

(d) selecting the cereblon modifying compound that does not induce the interaction between the SALL 4 and the cereblon as determined in step (c).

2. The method of claim 1 , further comprising

(i) determining a first protein level of SALL 4 in the sample prior to the administration of the cereblon modifying compound;

(ii) determining a second protein level of SALL 4 in the sample after the administration of the cereblon modifying compound;

(iii) comparing the first protein level and the second protein level of SALL 4 to determine if the cereblon modifying compound induces degradation of SALL 4 ; and

(iv) selecting the cereblon modifying compound that does not induce the degradation of SALL 4 as determined in step (iii).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2019
From: MATYSKIELA, MARY; CHAMBERLAIN, PHILIP; COUTO, SUZANA STURLINI; LU, GANG; STAMP, KATHERINE; SHERRATT, PHILIP J.; HUI, JULIA
To: CELGENE CORPORATION
Reel/Frame 048845/0505 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2019
From: MATYSKIELA, MARY; CHAMBERLAIN, PHILIP; COUTO, SUZANA STURLINI; LU, GANG; STAMP, KATHERINE; SHERRATT, PHILIP J.; HUI, JULIA
To: CELGENE CORPORATION
Reel/Frame 048845/0535 →
Continuity (3)
Provisional Application 62710401 · Feb 16, 2018
Provisional Application 62617112 · Jan 12, 2018
Related Publication 20190219562A1 · Jul 18, 2019
Cited By (4)
US 12,391,686 US 12,528,825 US 12,590,079 US 12,686,687